• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Section 32 Raises $740 Million Venture Fund

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    $RLAY
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology
    Get the next $COIN alert in real time by email

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare.

    "I'm so pleased that Nina has joined this team and I look forward to what this growing group will achieve together," commented Bill Maris, founder of Section 32. "What a privilege it is to close this fourth fund, and to thus have the continued opportunity to try to use capital as a lever to accelerate the profound positive impact technology can have on healthcare and humanity."

    The closing of Fund 4 brings assets under management for Section 32 to over $1.8B. To-date, Section 32 has made investments in more than 70 companies including Coinbase (NASDAQ:COIN), Crowdstrike (NASDAQ:CRWD), Relay Therapeutics (NASDAQ:RLAY), Thrive Earlier Detection (NASDAQ:EXAS), and Vir Biotechnology (NASDAQ:VIR). Section 32 has made eight investments from Fund 4 following an initial close of the fund in July 2021.

    Since its inception in 2017, Section 32 has grown to 16 people, including four managing partners: Bill Maris, Michael Pellini, M.D., Steve Kafka, Ph.D., and Andy Harrison, with offices in San Diego, Silicon Valley and Boston, MA. The team's cumulative career experience includes contributing to more than 130 company exits (through acquisition or public offerings) and helping to build and finance more than 50 companies with valuations in excess of $1 billion.

    With the closing of Fund 4, Section 32 added Nina Labatt to its team as its chief operating officer and chief financial officer. Nina brings more than two decades of experience to her new role and is recognized as an industry expert leading finance and operations in venture capital and private equity.

    "I'm delighted to join the team at Section 32 at this exciting time in the firm's growth," commented Nina Labatt. "I look forward to collaborating with the team to continue building world-class operations and finance functions that support our investing efforts."

    Most recently, Nina served as chief operating officer and general partner at Trinity Ventures, where she managed finance, marketing, data analytics, human resources, and legal for the firm. She also led internal strategic initiatives, structured and executed investment transactions with the investing team and participated in the firm's fundraising efforts. Previously, Ms. Labatt served as managing director, Private Equity Services for Silicon Valley Bank, as well as chief financial officer for Health Evolution Partners. Earlier in her career, Ms. Labatt was an investment banker for Goldman Sachs and Montgomery Securities. Ms. Labatt received a bachelor's degree in economics and a master's degree in international policy studies from Stanford University. She received her MBA from Harvard Business School. She was a founding member of the Northern California board of directors for the CFO Leadership Council and previously served as chairperson of the board of directors of VCBC, a non-profit association for finance professionals in venture capital.

    About Section 32

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html

    SOURCE Section 32

    Get the next $COIN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COIN
    $CRWD
    $EXAS
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    Coinbase Global Inc.
    $COIN
    10/3/2025$417.00Neutral → Buy
    Rothschild & Co Redburn
    Coinbase Global Inc.
    $COIN
    10/1/2025$410.00Buy
    BTIG Research
    CrowdStrike Holdings Inc.
    $CRWD
    9/25/2025$600.00Sector Perform → Sector Outperform
    Scotiabank
    CrowdStrike Holdings Inc.
    $CRWD
    9/24/2025$440.00Hold → Sell
    DZ Bank
    CrowdStrike Holdings Inc.
    $CRWD
    9/18/2025$450.00 → $500.00Outperform
    BMO Capital Markets
    Relay Therapeutics Inc.
    $RLAY
    9/4/2025$15.00Buy
    Guggenheim
    Vir Biotechnology Inc.
    $VIR
    9/3/2025$12.00Outperform
    Evercore ISI
    Vir Biotechnology Inc.
    $VIR
    8/27/2025$14.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coinbase Announces Date of Third Quarter 2025 Financial Results

    Coinbase Global, Inc. (the "Company" or "Coinbase") announced today that it will publish its third quarter 2025 shareholder letter, including financial results, on its Investor Relations website at investor.coinbase.com on Thursday, October 30, 2025, after market close. The Company will hold a question and answer session to discuss its financial results at 2:30 p.m. PT that same day. Starting on October 23 at 9:00 a.m. PT, all shareholders will be able to submit and upvote questions for Coinbase management by visiting here. This Q&A platform will remain open until 24 hours before the earnings call. Shareholders can email [email protected] for any support inquiries. The live we

    10/10/25 4:30:00 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

    – Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical trial builds on encouraging Phase 1 data of monotherapy VIR-5500 in late-line patients presented in January 2025 Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in Part 3 of the Company's Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs). VIR-5500 is an investigational PRO-XTEN® dual-masked T-cell engager (TCE) targeting prostate-specific membrane antigen (PSMA) and will be evaluated in partic

    10/9/25 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fal.Con Europe 2025 Sells Out, Demonstrating Global Demand as CrowdStrike Leads Cybersecurity in the AI Era

    More than 2,000 attendees from 900 organizations across 63 countries to converge in Barcelona for cybersecurity's fastest-growing global conference CrowdStrike (NASDAQ:CRWD) today announced Fal.Con Europe has sold out for the second consecutive year, underscoring global demand from cybersecurity in the agentic era. Building on the record-setting Fal.Con 2025 in Las Vegas, which drew more than 8,000 cybersecurity leaders, Fal.Con Europe will bring together over 2,000 security leaders from 63 countries at Fira Barcelona from November 4-6. With 40+ partner sponsors and more than 900 organizations represented, Fal.Con Europe sets a new benchmark as the premier cybersecurity conference in the

    10/8/25 8:00:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Coinbase Global upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Coinbase Global from Neutral to Buy and set a new price target of $417.00

    10/3/25 8:25:23 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    BTIG Research initiated coverage on Coinbase Global with a new price target

    BTIG Research initiated coverage of Coinbase Global with a rating of Buy and set a new price target of $410.00

    10/1/25 8:46:20 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    CrowdStrike upgraded by Scotiabank with a new price target

    Scotiabank upgraded CrowdStrike from Sector Perform to Sector Outperform and set a new price target of $600.00

    9/25/25 8:22:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $COIN
    $CRWD
    $EXAS
    $RLAY
    SEC Filings

    View All

    PRESIDENT Sentonas Michael sold $12,725,000 worth of shares (25,000 units at $509.00), decreasing direct ownership by 7% to 354,116 units (SEC Form 4)

    4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)

    10/10/25 8:30:06 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    SVP, General Counsel & Sec Herriott James sold $90,000 worth of shares (1,500 units at $60.00), decreasing direct ownership by 10% to 14,085 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    10/10/25 5:27:10 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Director Doyle James Edward sold $120,000 worth of shares (2,000 units at $60.00), decreasing direct ownership by 3% to 57,962 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    10/10/25 5:25:29 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 144 filed by Vir Biotechnology Inc.

    144 - Vir Biotechnology, Inc. (0001706431) (Subject)

    10/1/25 4:32:53 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Coinbase Global Inc.

    144 - Coinbase Global, Inc. (0001679788) (Subject)

    9/15/25 12:30:47 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation

    SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    9/8/25 11:46:16 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Jiko Announces Strategic Investments from Key Industry Players Including Coinbase and Blockstream Capital Partners

    Leading digital asset platforms choose Jiko to power safe, always-on storage and settlement Jiko, the only platform built 100% on U.S. T-bills to power the world's liquidity, today announced strategic backing by Coinbase (NASDAQ:COIN) and Blockstream Capital Partners. Alongside this investment, Jiko is entering new strategic partnerships with leading industry players, including Crypto.com, Blockstream Capital Partners, Bitso, and Coinbase. These strategic partners will join a growing number of institutions adopting Jiko as a banking partner to utilize its U.S. T-bill-based model for storage, settlements, and payments. "The crypto world moves in milliseconds. The fiat world takes days. T

    10/7/25 8:30:00 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    CrowdStrike Appoints Amjad Hussain as Chief Resilience Officer

    Appointment accelerates commitment to advancing cyber resilience across every part of the platform and business CrowdStrike (NASDAQ:CRWD) today announced the appointment of Amjad Hussain as chief resilience officer. Reporting directly to CEO and founder George Kurtz, Hussain will help shape how CrowdStrike advances resilience across its platform and business, accelerating CrowdStrike's defining principles of operational excellence and reliability across the company. He will also work across the cybersecurity ecosystem to raise the bar for resilience and help establish new industry best practices. "What defines CrowdStrike is how we execute relentlessly, transparently, and with resilienc

    9/30/25 8:00:00 AM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    CleanSpark Expands Capital Strategy with Additional $100M Bitcoin-Backed Credit Capacity from Coinbase Prime

    Proceeds to support strategic energy and compute growth Non-dilutive capital will be deployed into accretive assets across CleanSpark's portfolio  LAS VEGAS, Sept. 22, 2025 /PRNewswire/ -- CleanSpark, Inc. (NASDAQ:CLSK), America's Bitcoin Miner® (the "Company"), today announced that it has expanded its capital strategy by increasing its Bitcoin-backed credit facility with Coinbase Prime (NASDAQ:COIN) by $100 million. The $100 million in financing will be deployed into strategic capital expenditures, including expanding CleanSpark's energy portfolio, scaling its Bitcoin mining

    9/22/25 4:30:00 PM ET
    $CLSK
    $COIN
    Finance: Consumer Services
    Finance

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:44:24 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:40:50 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by CrowdStrike Holdings Inc.

    SC 13G/A - CrowdStrike Holdings, Inc. (0001535527) (Subject)

    11/14/24 1:22:38 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Financials

    Live finance-specific insights

    View All

    Coinbase Announces Date of Third Quarter 2025 Financial Results

    Coinbase Global, Inc. (the "Company" or "Coinbase") announced today that it will publish its third quarter 2025 shareholder letter, including financial results, on its Investor Relations website at investor.coinbase.com on Thursday, October 30, 2025, after market close. The Company will hold a question and answer session to discuss its financial results at 2:30 p.m. PT that same day. Starting on October 23 at 9:00 a.m. PT, all shareholders will be able to submit and upvote questions for Coinbase management by visiting here. This Q&A platform will remain open until 24 hours before the earnings call. Shareholders can email [email protected] for any support inquiries. The live we

    10/10/25 4:30:00 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Exact Sciences Schedules Third Quarter 2025 Earnings Call

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: Monday, November 3, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers

    10/8/25 7:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    CrowdStrike Reports Second Quarter Fiscal Year 2026 Financial Results

    Achieves record Q2 net new ARR of $221 million and reacceleration ahead of expectations Ending ARR grows 20% year-over-year to reach $4.66 billion Delivers record Q2 cash flow from operations of $333 million and record Q2 free cash flow of $284 million CrowdStrike Holdings, Inc. (NASDAQ:CRWD), today announced financial results for the second quarter fiscal year 2026, ended July 31, 2025. "With reacceleration a quarter ahead of our expectations, CrowdStrike delivered an exceptional Q2. Record Q2 net new ARR of $221 million, over 1,000 Flex customers, and more than 100 re-flexes highlight CrowdStrike as the leader in cybersecurity consolidation," said George Kurtz, Founder and CEO

    8/27/25 4:10:00 PM ET
    $CRWD
    Computer Software: Prepackaged Software
    Technology